+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Fungal Keratitis Treatment Market by Treatment Modality, Drug Class, End User, Distribution Channel - Global Forecast to 2030- Product Image
Fungal Keratitis Treatment Market by Treatment Modality, Drug Class, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Fungal Keratitis Treatment Market by Treatment Modality, Drug Class, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674168
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Fungal Keratitis Treatment Market grew from USD 891.25 million in 2024 to USD 941.70 million in 2025. It is expected to continue growing at a CAGR of 5.40%, reaching USD 1.22 billion by 2030.

Laying the Groundwork for Comprehensive Market Understanding

Fungal keratitis represents a significant clinical challenge characterized by infections that can progress rapidly if not diagnosed and treated effectively. This condition, involving the corneal stroma, demands prompt intervention to prevent vision loss or irreversible ocular damage. Over recent years, evolving pathogen profiles, emerging antifungal resistance, and varying access to advanced treatment modalities have underscored the need for a nuanced understanding of therapeutic options and market drivers.

This executive summary provides a distilled overview of the multifaceted factors shaping the fungal keratitis treatment landscape. It synthesizes clinical trends, technological advancements, evolving regulatory environments, and the influence of recent policy shifts. Special attention is given to the interplay between therapeutic modalities, drug class innovations, end-user preferences, and distribution pathways that collectively drive market dynamics.

Decision-makers will find a concise yet comprehensive presentation of actionable insights that spotlight transformative shifts, regional variances, competitive positioning, and strategic imperatives. By integrating clinical realities with market forces, this summary offers a foundational framework to guide investment decisions, portfolio management, and long-term strategic planning in the field of fungal keratitis treatment.

Navigating Shifting Paradigms in Fungal Keratitis Care

The fungal keratitis treatment landscape is undergoing a series of transformative shifts driven by scientific breakthroughs, evolving clinical practices, and heightened stakeholder collaboration. Advances in diagnostic modalities, including in vivo confocal microscopy and polymerase chain reaction assays, have accelerated pathogen identification, enabling earlier intervention and more targeted therapies. These diagnostic improvements are complemented by refinements in topical and systemic antifungal formulations that enhance ocular penetration and reduce systemic toxicity.

Concurrently, surgical interventions are benefiting from minimally invasive techniques and laser-assisted procedures that offer improved corneal preservation. This evolution in surgical practice is harmonizing with the growing adoption of combination treatment regimens that integrate topical agents with systemic therapies to address refractory cases. Furthermore, there is an increasing emphasis on novel drug delivery systems such as nanocarriers and sustained-release implants, which promise to overcome adherence challenges and optimize therapeutic concentrations at the infection site.

Stakeholders across the value chain are collaborating to establish standardized treatment protocols and real-world evidence networks. Such initiatives are reshaping clinical guidelines and reimbursement frameworks, ultimately facilitating broader access to advanced therapies. As these paradigm shifts converge, they pave the way for more personalized, efficient, and cost-effective management of fungal keratitis.

Assessing the Ripple Effects of 2025 US Tariff Policies

The implementation of new tariff measures in 2025 by United States authorities has introduced a complex layer of cost considerations for importers of active pharmaceutical ingredients and finished formulations. Increased duties on key raw materials used in antifungal synthesis have elevated manufacturing expenses, prompting some producers to reassess supply chain configurations. In response, certain manufacturers have explored the relocation of production facilities or the diversification of sourcing strategies to mitigate the impact of higher input costs.

These tariff-induced pressures are also reverberating through pricing negotiations with payers and health systems. In an effort to maintain margin stability, several companies have resorted to localized price adjustments, which in turn influence patient access and reimbursement policies. Additionally, distributors and wholesalers have had to recalibrate their logistical models to account for shifting duty burdens, resulting in operational realignments aimed at preserving supply continuity.

Despite these challenges, there is evidence that stakeholders are leveraging tariff disruptions as a catalyst for greater vertical integration and enhanced supply chain resilience. Investments in domestic manufacturing capabilities and strategic partnerships have emerged as viable counter-measures that not only address immediate cost concerns but also align with broader industry objectives of ensuring sustainable access to critical antifungal therapies.

Unveiling Segmentation Trends Driving Treatment Strategies

Critical segmentation analysis reveals the nuanced drivers of growth across treatment modalities, drug classes, end users, and distribution channels. Within treatment modalities, topical antifungals continue to dominate early-stage management due to their direct ocular application and favorable safety profile, whereas systemic antifungals are reserved for severe or recalcitrant infections that require comprehensive tissue bioavailability. Surgical interventions, although applied in a smaller subset of cases, are increasingly supported by adjunct pharmacological strategies to improve clinical outcomes.

Examining drug class dynamics uncovers a sustained preference for azoles, particularly triazoles such as voriconazole and itraconazole, which balance broad-spectrum coverage with manageable safety profiles. Imidazole derivatives like econazole and ketoconazole retain niche roles in specific geographic markets. Echinocandins, notably caspofungin and micafungin, are recognized for their efficacy against resistant strains, while polyene agents such as amphotericin B and natamycin remain foundational therapies due to their potent fungicidal activity.

End users exhibit distinct procurement behaviors, with ambulatory surgical centers and eye specialty centers favoring advanced formulation portfolios, and clinics, whether multi-specialty or specialized, emphasizing cost-effective options that streamline patient throughput. Hospitals, both private and public, balance efficacy, formulary constraints, and inpatient care requirements when selecting therapeutic regimens. Distribution channels underscore the coexistence of traditional offline retail outlets alongside burgeoning online platforms that cater to remote and underserved regions, expanding patient access through digital engagement.

Regional Currents Shaping Market Expansion

Regional landscapes exhibit divergent growth trajectories shaped by economic conditions, healthcare infrastructure, and regulatory environments. In the Americas, established healthcare networks and robust reimbursement frameworks underpin rapid adoption of advanced antifungal therapies, complemented by strong partnerships between local manufacturers and global distributors. Market maturation in this region is supported by ongoing clinical research collaborations that accelerate access to breakthrough treatments.

In Europe, Middle East & Africa, varied regulatory harmonization efforts are fostering a more cohesive approach to antifungal approvals. While Western European markets benefit from consistent guideline adherence and high per-capita healthcare spending, emerging economies in the Middle East and Africa are witnessing targeted investments in diagnostic capabilities and capacity building, laying the groundwork for future market expansion.

Asia-Pacific stands out for its growing prevalence of fungal keratitis driven by climatic and occupational factors. Rapid improvements in healthcare delivery systems and rising awareness among eye care professionals have led to increased demand for topical and systemic antifungal agents. Regional manufacturers are also advancing generic portfolios, creating competitive pressure that encourages pricing optimization and broader patient access across both urban centers and rural communities.

Highlighting Leading Innovators and Competitive Landscapes

The competitive landscape is marked by a blend of multinational pharmaceutical leaders and specialized ophthalmic firms driving innovation across the value chain. Novartis has strengthened its position through strategic acquisitions and the introduction of next-generation triazole formulations. Pfizer’s antifungal division has capitalized on advanced drug delivery technologies, enhancing systemic therapy profiles. Bausch + Lomb continues to leverage its deep ophthalmic expertise to expand topical offerings with improved tolerability.

Specialty companies such as Santen and F. Hoffmann-La Roche have differentiated themselves through targeted research collaborations that prioritize rapid diagnostic integration and adaptive clinical trial designs. Amphastar Pharmaceuticals has gained traction by focusing on generic polyene and azole portfolios, while Sun Pharmaceutical has harnessed scale advantages to optimize production efficiencies and distribution networks across emerging markets.

Partnerships between these players and contract manufacturing organizations are further accelerating time-to-market for critical therapies. Collaborative efforts aimed at novel formulation development, including sustained-release systems and nanoparticle carriers, underscore a collective drive to address unmet clinical needs and reinforce competitive positioning within the fungal keratitis treatment arena.

Charting Strategic Recommendations for Industry Stakeholders

Industry leaders can fortify their strategic positioning by aligning research and development priorities with evolving clinical demands. Investing in expedited diagnostic-therapeutic platforms that integrate point-of-care testing with immediate treatment initiation will enhance clinical outcomes and reinforce value propositions. Moreover, exploring partnerships with regional manufacturers can mitigate supply chain disruptions and optimize cost structures, particularly in tariff-sensitive environments.

Expanding patient access through digital health initiatives, such as tele-ophthalmology and e-commerce distribution, presents a compelling avenue for growth in underserved areas. Tailored education programs for eye care professionals on emerging treatment protocols will further drive adoption of advanced therapies. Simultaneously, forging collaborations with reimbursement bodies to establish value-based pricing models can ensure sustainable market uptake and favorable formulary placements.

Finally, maintaining a proactive approach to regulatory engagement-emphasizing real-world evidence generation, post-market surveillance, and adaptive trial frameworks-will enable stakeholders to anticipate policy shifts and respond agilely to evolving market conditions.

Upholding Analytical Integrity Through Rigorous Research Methods

This analysis is grounded in a multi-tiered research framework combining primary interviews with ophthalmologists, key opinion leaders, and supply chain experts, alongside secondary data drawn from peer-reviewed journals, regulatory filings, and industry white papers. Quantitative insights were validated through triangulation of market intelligence, clinical trial registries, and healthcare utilization databases to ensure robust evidence synthesis.

A systematic review of tariff documentation, trade data, and policy briefs was undertaken to assess the impact of 2025 tariff changes. Segmentation analyses were informed by product registries, procurement records, and distribution channel audits to capture granular trends across modalities, drug classes, end users, and channels. Regional insights were contextualized through country-level epidemiological studies and healthcare infrastructure assessments.

Quality assurance protocols included methodological peer review, data validation checks, and consistency audits to uphold analytical integrity. All findings were cross-verified with external experts to ensure objectivity and relevance to current market dynamics.

Drawing Conclusions and Charting Future Directions

The collective insights presented in this executive summary underscore the dynamic interplay between clinical innovation, policy environments, and competitive forces that define the fungal keratitis treatment market. As diagnostic capabilities evolve and therapeutic portfolios diversify, stakeholders are presented with both challenges and opportunities to enhance patient outcomes.

Adaptive strategies that integrate advanced drug delivery systems, strategic tariff mitigation, and targeted regional partnerships will be critical for sustained growth. By leveraging segmentation insights and anticipating regulatory shifts, industry leaders can position themselves to capitalize on emerging trends while addressing unmet clinical needs. Ultimately, the strategic alignment of research, manufacturing, and market access initiatives will determine success in a landscape characterized by rapid transformation and increasing complexity.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Modality
    • Surgical Interventions
    • Systemic Antifungals
    • Topical Antifungals
  • Drug Class
    • Azoles
      • Imidazoles
        • Econazole
        • Ketoconazole
      • Triazoles
        • Fluconazole
        • Itraconazole
        • Voriconazole
    • Echinocandins
      • Caspofungin
      • Micafungin
    • Polyenes
      • Amphotericin B
      • Natamycin
  • End User
    • Ambulatory Surgical Centers
    • Clinics
      • Multi-Specialty Clinics
      • Specialty Clinics
    • Eye Specialty Centers
    • Hospitals
      • Private Hospitals
      • Public Hospitals
  • Distribution Channel
    • Offline Retail
    • Online Retail
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Alcon Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Viatris Inc.
  • Sandoz International GmbH
  • Fresenius Kabi AG
  • Sun Pharmaceutical Industries Limited
  • Cipla Limited
  • Bausch & Lomb Incorporated
  • Ajanta Pharma Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Fungal Keratitis Treatment Market, by Treatment Modality
8.1. Introduction
8.2. Surgical Interventions
8.3. Systemic Antifungals
8.4. Topical Antifungals
9. Fungal Keratitis Treatment Market, by Drug Class
9.1. Introduction
9.2. Azoles
9.2.1. Imidazoles
9.2.1.1. Econazole
9.2.1.2. Ketoconazole
9.2.2. Triazoles
9.2.2.1. Fluconazole
9.2.2.2. Itraconazole
9.2.2.3. Voriconazole
9.3. Echinocandins
9.3.1. Caspofungin
9.3.2. Micafungin
9.4. Polyenes
9.4.1. Amphotericin B
9.4.2. Natamycin
10. Fungal Keratitis Treatment Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Clinics
10.3.1. Multi-Specialty Clinics
10.3.2. Specialty Clinics
10.4. Eye Specialty Centers
10.5. Hospitals
10.5.1. Private Hospitals
10.5.2. Public Hospitals
11. Fungal Keratitis Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Offline Retail
11.3. Online Retail
12. Americas Fungal Keratitis Treatment Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Fungal Keratitis Treatment Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Fungal Keratitis Treatment Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Alcon Inc.
15.3.2. Santen Pharmaceutical Co., Ltd.
15.3.3. Pfizer Inc.
15.3.4. Viatris Inc.
15.3.5. Sandoz International GmbH
15.3.6. Fresenius Kabi AG
15.3.7. Sun Pharmaceutical Industries Limited
15.3.8. Cipla Limited
15.3.9. Bausch & Lomb Incorporated
15.3.10. Ajanta Pharma Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. FUNGAL KERATITIS TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. FUNGAL KERATITIS TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. FUNGAL KERATITIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC FUNGAL KERATITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. FUNGAL KERATITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. FUNGAL KERATITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. FUNGAL KERATITIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY SYSTEMIC ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TOPICAL ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECONAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY KETOCONAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CASPOFUNGIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY MICAFUNGIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY NATAMYCIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY MULTI-SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY EYE SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 68. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 69. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 71. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 72. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 73. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 74. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 75. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 77. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 78. CANADA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 80. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 82. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 83. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 84. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 85. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 86. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 88. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. GERMANY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 136. GERMANY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. GERMANY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 138. GERMANY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 139. GERMANY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 140. GERMANY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 141. GERMANY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 142. GERMANY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. GERMANY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 144. GERMANY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 145. GERMANY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. FRANCE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 147. FRANCE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. FRANCE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 149. FRANCE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 150. FRANCE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 151. FRANCE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 152. FRANCE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 153. FRANCE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. FRANCE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 155. FRANCE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 156. FRANCE FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. ITALY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 169. ITALY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. ITALY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 171. ITALY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 172. ITALY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 173. ITALY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 174. ITALY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 175. ITALY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. ITALY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 177. ITALY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 178. ITALY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. SPAIN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 180. SPAIN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 181. SPAIN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 182. SPAIN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 183. SPAIN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 184. SPAIN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 185. SPAIN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 186. SPAIN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. SPAIN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 188. SPAIN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 189. SPAIN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. DENMARK FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 224. DENMARK FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 225. DENMARK FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 226. DENMARK FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 227. DENMARK FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 228. DENMARK FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 229. DENMARK FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 230. DENMARK FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. DENMARK FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 232. DENMARK FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 233. DENMARK FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. QATAR FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 246. QATAR FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. QATAR FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 248. QATAR FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 249. QATAR FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 250. QATAR FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 251. QATAR FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 252. QATAR FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. QATAR FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 254. QATAR FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 255. QATAR FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. FINLAND FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 257. FINLAND FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 258. FINLAND FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 259. FINLAND FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 260. FINLAND FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 261. FINLAND FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 262. FINLAND FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 263. FINLAND FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. FINLAND FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 265. FINLAND FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 266. FINLAND FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. SWEDEN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 268. SWEDEN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. NIGERIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 279. NIGERIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. EGYPT FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 290. EGYPT FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 291. EGYPT FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 292. EGYPT FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 293. EGYPT FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 294. EGYPT FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 295. EGYPT FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 296. EGYPT FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. EGYPT FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 298. EGYPT FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 299. EGYPT FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. TURKEY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 301. TURKEY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 302. TURKEY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 303. TURKEY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 304. TURKEY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 305. TURKEY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 306. TURKEY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 307. TURKEY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. TURKEY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 309. TURKEY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 310. TURKEY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. ISRAEL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TRIAZOLES, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. ISRAEL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 320. ISRAEL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 321. ISRAEL FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 322. NORWAY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 323. NORWAY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 324. NORWAY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
TABLE 325. NORWAY FUNGAL KERATITIS TREATMENT MARKET SIZE, BY IMIDAZOLES, 2018-2030 (USD MILLION)
TABLE

Companies Mentioned

The companies profiled in this Fungal Keratitis Treatment market report include:
  • Alcon Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Viatris Inc.
  • Sandoz International GmbH
  • Fresenius Kabi AG
  • Sun Pharmaceutical Industries Limited
  • Cipla Limited
  • Bausch & Lomb Incorporated
  • Ajanta Pharma Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 941.7 Million
Forecasted Market Value ( USD ) by 2030 $ 1220 Million
Compound Annual Growth Rate5.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Fungal Keratitis Treatment - Global Strategic Business Report - Product Image

Fungal Keratitis Treatment - Global Strategic Business Report

  • Report
  • 484 Pages
  • Global
From
Global Fungal Keratitis Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global Fungal Keratitis Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 119 Pages
  • Global
From
Fungal Keratitis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Fungal Keratitis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 227 Pages
  • Global
From
Fungal Keratitis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Fungal Keratitis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Fungal Keratitis Treatment Market 2024-2028 - Product Image

Fungal Keratitis Treatment Market 2024-2028

  • Report
  • 170 Pages
  • Global
From

About the Fungal Keratitis Drug Market

Fungal Keratitis is an infection of the cornea caused by a fungus. It is a common cause of vision loss and can be treated with antifungal drugs. The Fungal Keratitis Drug market is a subset of the Optical Disorders Drugs market, which includes drugs used to treat a variety of eye diseases. Fungal Keratitis Drugs are used to treat the infection and reduce the risk of vision loss. These drugs are typically administered topically, either as eye drops or ointments. The Fungal Keratitis Drug market is highly competitive, with a number of companies offering products. Some of the major players in the market include Allergan, Bausch + Lomb, Santen Pharmaceuticals, and Sun Pharmaceuticals. Other companies in the market include Merck, Pfizer, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.